Study finds Tasylol safe in certain surgeries
German drugmaker Bayer AG's surgical clotting agent Trasylol (aprotinin injection) appears safe during on-pump cardiac surgery, according to a report published in The Lancet, February 8. However, the team of UK scientists noted that Trasylol plus angiotensin-converting enzyme inhibitors during off-pump cardiac surgery is associated with a significant risk of postoperative renal dysfunction.
The article's authors did a retrospective study of the effect of Trasylol on renal dysfunction, analyzing 9,875 patients. In 5,434 subjects undergoing on-pump cardiac surgery, the odds ratio between Trasylol and an increased risk of renal dysfunction without ACE inhibitor was 1.81 (p=0.162) and with ACE inhibitor 1.73 (p=0
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze